An interventional study of NIATx Coaching in Opioid Use Disorder, HIV Infections and Hepatitis C, sponsored by Yale University. Active, not recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Yale University · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Opioid-Related Disorders by Yale University — 20 open to participants now, 24 under way, 1 of them phase 3. Opioid-Related Disorders · Yale University.
Among the 106 studies in Opioid-Related Disorders by Yale University, this one is the 67th largest by enrollment of the 94 interventional ones that give a count, is one of 8 that started in 2023, is one of 44 with no phase, reaches primary completion later than 9 of the 23 other live ones, and was the 83rd registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →20 of the 106 studies in Opioid-Related Disorders by Yale University are open now, in 4 countries. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 25–65 · Healthy volunteers
Yale University · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 26 · Phase 3 7 · Phase 4 9
First in 1988; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 62 across the 94 interventional studies, 108 across the 11 observational. Of the 75 that completed or were terminated, 27 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
10 of the studies in Opioid-Related Disorders by Yale University that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06494904Phase 3Yale UniversityStandard Versus High Dose ED-Initiated Buprenorphine Induction | 2027-09 |
| NCT05333341Yale UniversityPain Care at Home to Amplify Function (Pain CHAMP) | 2026-11-30 |
| NCT01730781Yale UniversityImaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning | 2026-12 |
| NCT06160284Yale UniversityExploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD) | 2027-01 |
| NCT06207162Yale UniversityLongitudinal Neural Fingerprinting of Opioid-use Trajectories | 2027-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 106 studies in Opioid-Related Disorders by Yale University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate an intervention strategy in introducing screen/evaluate/treat (SET) procedures for HIV/ hepatitis C/ and Opioid Use Disorder in Primary Care Clinics in West Virginia.
The main questions it aims to answer are:
To integrate HIV/HCV/ OUD services into Primary Care Clinics (PCC), the investigators will introduce screen/evaluate/treat (SET) procedures for HIV/hepatitis C (HCV)/ Opioid Use Disorder (OUD) in PCCs in rural WV where ECHO and WV Hepatitis Academic Mentoring Partnership (WVHAMP) will support clinical skills for Primary Care Provider (PCPs) and where NIATx process improvement tools will be used to guide adoption and scale-up of SET procedures to achieve integration. Using a step-wedge design with 20 PCCs, the investigators will conduct a Type 3 Hybrid implementation trial and examine the extent to which our SET processes are achieved through enhanced electronic health record (EHR) tools, NIATx facilitation and ECHO and WVHAMP collaborative learning. Implementation outcomes include adoption of screening and treating with three distinct but linked evidence based practices (EBPs) for OUD, HIV and HCV in PCCs. Effectiveness outcomes will include quality health indicators (QHIs) for primary care, HIV, HCV and OUD.
This project is separated into two Phases. Phase 1 includes Nominal Group Technique focus groups and anonymous staff surveys at the 20 PCCs to identify barriers and facilitators to integrating these evidence based practices. Phase 2 is an evaluation of deidentified reports from the PCCs Electronic Health Records. In Phase 2, randomized sites will start NIATx activities, including a series of rapid-cycle Plan-Do-Study-Act (PDSA) activities. The first 6 months will include intensive coaching from a certified NIATx coach and enhanced by support from ECHO \& the WVHAMP to teach subspecialty clinical expertise. During an 18-month follow-up, the investigators will assess the sustainability of these practice changes. Effectiveness outcomes will include a set of nationally recommended quality health indicators (QHIs) to measure quality care. This project is a collaboration between Yale University, West Virginia University (WVU), and the West Virginia Primary Care Association.
Aim 1 (Phase 1):
Identify the barriers and facilitators for a diverse group of PCCs throughout WV, a mostly rural state that is profoundly impacted by OUD-associated HIV/HCV outbreaks, focusing on screening for and prescribing evidence-based treatment [medication for opioid use disorder (MOUD), Treatment as Prevention (TasP), pre-exposure prophylaxis (PrEP), and curative hepatitis C (HCV) treatment] for OUD, HIV and HCV.
Aim 2 (Phase 2):
Using a step-wedge design with 20 PCCs, the investigators will conduct a Type 3 hybrid implementation trial using the Integrated Promoting Action on Research Implementation in Health Services (iPARiHS) framework to assess the extent to which our SET processes are achieved through enhanced EHR tools, NIATx facilitation and ECHO-supported collaborative learning. Implementation outcomes include adoption of screening and implementation of three distinct but linked EBPs for OUD, HIV and HCV in PCCs. Effectiveness outcomes will include quality health indicators (QHIs) for primary care, HIV, HCV and OUD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Federally Qualified Health Centers (FQHCs) and Look-Alike FQHC Primary Care Clinics in West Virginia providing adult care
Exclusion Criteria:
Each group of clinics will receive the same intervention in a step-wedge design, starting every 6-months.
Behavioral: NIATx Coaching
The intervention will consist of: 1. a Nominal Group Technique session to identify priorities in integrating HIV/HCV/MOUD 2. rapid cycle improvement coaching sessions from a NIATx coach, using data dashboards and screening alerts to improve identification and treatment for HIV/HCV/OUD 3. training for primary care providers
Organizational Readiness and Staff Attitudes towards integration of OUD, HIV, HCV services into primary care clinics
Staff survey results on organizational capacity, readiness to change, organizational functioning and social dominance orientation, and resistance to change.
Time frame: Every 6 months for 24 months
Integration of services
Adoption of screening and implementation of best evidence-based practices. Quality health indicators (QHIs) for primary care - OUD, HIV \& HCV documented in electronic health record data.
Time frame: 24 months
Number of patients screened for opioid use disorder (OUD)
Screening result for opioid use disorder documented in electronic health record (EHR)
Time frame: 18 months
Number of patients initiated on medications for OUD
Prescription medication for OUD; prescription dates, medication type
Time frame: 18 months
Number of patients screened for HIV
Lab ordered and result for HIV test entered in EHR
Time frame: 18 months
Number of patients initiated on antiretroviral medication (ART) for HIV
For those with a positive HIV test result, prescription medication for HIV; prescription dates
Time frame: 18 months
Number of patients screened for Hepatitis C (HCV)
Lab result ordered for HCV antibody / reflex polymerase chain reaction (PCR), result entered in EHR
Time frame: 18 months
Number of patients initiated on medication for HCV
For those with a positive HCV PCR test, documented in EHR prescription medication for HCV; prescription dates; fibrosis score
Time frame: 18 months
Number of patients prescribed PrEP
For those with a negative HIV result, prescription medication for PrEP; medication type; prescription dates; lab orders
Time frame: 18 months
Number of patients with sustained viral response for HCV
For those with HCV medication prescription; Viral load results in EHR after recommended treatment
Time frame: 18 months
Number of patients retained on medication for OUD for at least 6 months
For those with prescription for medication for OUD; documentation in EHR of repeated prescription orders
Time frame: 6 months
Number of patients retained on medication (ART) for HIV
For those with new prescription for medication for HIV; documentation in EHR of repeated prescriptions up to 6 and 12 months
Time frame: 12 months
Number of patients with Viral Suppression for HIV
For those with new HIV diagnosis; documentation in EHR of viral suppression defined as HIV RNA \<200 copies/µl, at 6 and 12 months after prescription
Time frame: 12 months
Number of patients on PrEP to prevent HIV
Documentation of negative HIV labs in EHR every 3 months
Time frame: 12 months
Quality Health Indicator (QHI) score for Primary Care screening variables
QHI-PC score based on documentation of screening (limited age/sex) for hypertension, diabetes, hyperlipidemia, HIV, HCV, hepatitis B (HBV), syphilis, cervical cancer, breast cancers, prostate cancer, herpes simplex virus (HSV) serology, latent tuberculosis (TB), colorectal cancer, depression, chlamydia, gonorrhea.
Time frame: 18 months
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2023 (actual). Primary completion is estimated for May 2027, 52 months after the start.
Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 52 months is above that.
Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.